https://www.selleckchem.com/pr....oducts/relacorilant.
67, 95% CI 0.53-0.86, p = 0.0012, 25 events per 1000 patients prevented). Conclusion The CHA2DS2-VASc and CHADS2 scores can be used in patients with chronic CAD and/or PAD to identify patients who are at highest risk of MACE. Those identified at highest risk by CHADS2 scores had greatest benefit from dual pathway inhibition with rivaroxaban plus aspirin. Clinical Trial Registration NCT01776424. To determine whether rat offspring born under conditions of chronic intermittent hypoxia (CIH) would develop systemic inflammation and be s
Like
Comment
Share
